Silver Lake Acquires Grupo BC from L-GAM
19.10.2021 10:00:00 EEST | Business Wire | Press release
Grupo BC, the leading mortgage management, legal and digital services provider to the financial sector in Iberia and Latin America, today announced that Silver Lake, a leading global technology investment firm, together with Grupo BC’s founding shareholders and management team, will acquire 100% of the company from majority holders L-GAM in order to foster the next phase of Grupo BC’s growth and value creation.
Santiago Bellver, Chairman of Grupo BC, and Xavier Costa, CEO of Grupo BC, said: “We are grateful to L-GAM for the support and collaboration over the six years of their investment in Grupo BC, and delighted about the new partnership with Silver Lake, a leading global technology investor which has placed their trust in us and with whom we will be able to strengthen our organic growth thanks to their technological expertise and through selective acquisitions. We will shortly communicate the objectives of our strategic plan and the composition of the new Board of Directors.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Grupo BC is an outstanding company with a unique value proposition as a scaled and tech-enabled provider of mission-critical services and software to financial institutions across Iberia and Latin America. We are impressed by the way Santiago, Xavier and the rest of the team have developed and continuously digitalized the Grupo BC platform over the years, building it into the partner of choice for clients across its ecosystem. Investing in impactful, leading and technology-enabled business models is at the core of Silver Lake’s DNA, and we feel privileged to partner with management as Grupo BC enters a new phase of organic and inorganic growth.”
Felipe Merry del Val and Tito Soso, Partners at L-GAM, added: “Our journey with Grupo BC has been a remarkable story of transformation, several fold growth and success, and importantly a hugely rewarding partnership with a world-class management team led by Chairman Santiago Bellver and CEO Xavier Costa, whom we thank for the tremendous effort and achievement. We wish Grupo BC continued success in their future exciting endeavours.”
Founded in 1974 and headquartered in Madrid, Grupo BC is the leading tech-enabled processing platform, software and services provider for mortgage management, online mortgage brokerage, legal solutions (claims processing and loan management), and digital solutions to the financial sector in Spain, Portugal, Mexico, Brazil, Colombia, Chile and Peru. Grupo BC is a market leader across its key focus areas with more than 500,000 mortgage files processed per year and 5,300 employees. For more information, please visit https://www.grupobc.com.
Silver Lake’s investment is intended to further product development in order to strengthen and expand Grupo BC’s solution range as well as to continue its track-record of pioneering digital innovation, consistent with management’s clear focus on building out Grupo BC’s software and data analytics capabilities to enhance its client-centric solutions and drive continued organic and inorganic growth.
The transaction is anticipated to close in November 2021. Further terms of the investment are not being disclosed. Socios Financieros and Canson Capital Partners served as the financial advisors to Grupo BC and its shareholders. dwf-RCD served as the legal advisor to Grupo BC and its shareholders. Paul, Weiss, Rifkind, Wharton & Garrison LLP and Uría Menéndez served as the legal advisor to Silver Lake.
About Silver Lake
Silver Lake is a global technology investment firm, with more than $88 billion in combined assets under management and committed capital and a team of professionals based in North America, Europe and Asia. Silver Lake's portfolio companies collectively generate more than $221 billion of revenue annually and employ more than 526,000 people globally. For more information about Silver Lake and its portfolio, please visit http://www.silverlake.com.
About L-GAM
L-GAM is an international investment company founded in 2013 by its professionals in partnership with the Princely House of Liechtenstein and other major European, Asian and American families. Its unique and differentiated business model is based on a long term, industrial like investment focus in partnership with highly reputed SMEs throughout Europe. For more information about L-GAM, please visit http://www.l-gam.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005511/en/
Contact information
Media
For Silver Lake:
Spain: Paula Bonet, paula.bonet@edelman.com, +34 629 814 440
International: Jess Gill, Edelman Smithfield, silverlakemedia@edelman.com, +44 (0)7980 684 247
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom